Puma Biotechnology (PBYI) Other Non-Current Liabilities (2019 - 2025)

Puma Biotechnology (PBYI) has 7 years of Other Non-Current Liabilities data on file, last reported at $1.8 million in Q1 2025.

• Quarterly Other Non-Current Liabilities rose 1357.02% year-over-year to $1.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.8 million (up 1357.02% YoY) and the FY2024 annual result came in at $121000.0, changed 0.0% from the prior year.
• Other Non-Current Liabilities climbed to $1.8 million in Q1 2025, from $121000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $7.6 million in Q2 2023 to a low of $37000.0 in Q3 2022.
• A 5-year average of $2.4 million and a median of $756000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities surged 16178.38% — and 2022, when it slumped 99.39%.
• Tracing PBYI's Other Non-Current Liabilities over 5 years: stood at $5.5 million in 2021, then tumbled by 99.32% to $37000.0 in 2022, then jumped by 227.03% to $121000.0 in 2023, then changed by 0.0% to $121000.0 in 2024, then surged by 1357.02% to $1.8 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $1.8 million (Q1 2025), $121000.0 (Q4 2024), and $121000.0 (Q3 2024), per Business Quant data.